EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...